Seegene said it has developed a COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction, according to a news release.
The new variant test – the Allplex SARS-CoV-2 Variants I Assay – can identify major genetic variations that have originated in the United Kingdom, South Africa Japan and Brazil. It also can pre-screen a suspicious new variant, the company, based in South Korea, said.
However, Seegene has not yet filed an application with the U.S. Food and Drug Administration (FDA) for emergency use authorization for the test.
By utilizing Seegene’s big data auto-surveillance in silico system, the company said it is closely monitoring and analyzing a worldwide database on COVID-19 and its variants, allowing the company to respond quickly with product developments.
